Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain

BACKGROUND: Treatment of schizophrenia requires long-term medication to prevent relapse. Treatment nonadherence may increase the risk of relapse, leading to increased hospitalizations and emergency room (ER) visits. Long-acting injectables (LAIs) such as paliperidone palmitate have improved treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez‐Rojas, Luis, Sánchez-Alonso, Sergio, García Dorado, Marta, López Rengel, Paola M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095535/
https://www.ncbi.nlm.nih.gov/pubmed/35460508
http://dx.doi.org/10.1007/s40263-022-00917-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095535/
https://www.ncbi.nlm.nih.gov/pubmed/35460508
http://dx.doi.org/10.1007/s40263-022-00917-1

Ejemplares similares